Michael Buckstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Buckstein has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Erin Moshier
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
5 shared publicationsKenneth Rosenzweig
Departments of Radiation Oncology
5 shared publicationsMyron Schwartz
Surgery
5 shared publicationsEdward Kim
Interventional Radiology
4 shared publicationsMeng Ru
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA
4 shared publications- Eric J. Lehrer
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (2) , 101683
External beam radiation for HCC: Ready for incorporation into guidelines?
- 27 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (2) , 101683
Open AccessExternal beam radiation for HCC: Ready for incorporation into guidelines?
- 31 October 2025
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (1)
Motivators for sexual activity among women who are cancer survivors: a cross-sectional study
- 31 October 2025
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (1)
Motivators for sexual activity among women who are cancer survivors: a cross-sectional study
- Open Access
- 15 July 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (10) , 101856
Concurrent Radiation and Immunotherapy for Unresectable Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombus
- 15 July 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 10 (10) , 101856
Open AccessConcurrent Radiation and Immunotherapy for Unresectable Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombus
- 15 May 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (2) , 339-340
Ablative Radiation for Oligoprogression: Another Promising but Unproven Role for Radiation in Hepatocellular Carcinoma
- 15 May 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (2) , 339-340
Ablative Radiation for Oligoprogression: Another Promising but Unproven Role for Radiation in Hepatocellular Carcinoma
- 1 January 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (6) , 296.e9-296.e16
Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer
- 1 January 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (6) , 296.e9-296.e16
Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer
- 1 December 2022
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 18 (6) , 61-67
What Rectal Cancer Patients May Be Able to Safely Avoid Radiation?
- 1 December 2022
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 18 (6) , 61-67
What Rectal Cancer Patients May Be Able to Safely Avoid Radiation?
- Open Access
- 5 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2481
Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
The breakthrough of a limited number of clones while on immune checkpoint inhibitors (ICIs), known as oligoprogression, has been previously described. The benefit of ablative radiation therapy (RT) directed at these clones, as opposed to changing systemic therapy, is unclear. We analyzed 30 patients with advanced solid tumors, the majority of whom (23/30, 86.7%) had either hepatocellular or urothelial carcinoma, who experienced oligoprogression on ICIs and were referred for RT. In this study, oligoprogression was defined as having experienced progression at three or fewer metastatic sites outside of the brain after achieving at least stable disease on ICIs for a minimum of three months. The median time to oligoprogression was 11.1 months from the initiation of immunotherapy. 24 patients had one oligoprogressive lesion and six had two. The median radiation dose delivered was 4650 cGy in a median of five fractions. The median progression-free survival (PFS) after RT was 7.1 months, and the time to oligoprogression was not a significant predictor of PFS2. 26 patients continued on ICIs after RT. While 17 patients subsequently progressed, 15 did so at three or fewer metastatic sites and could have theoretically stood to benefit from an additional course of salvage RT to further extend the lifespan of their ICIs. Overall survival at 6, 12, and 24 months was 100.0%, 96.3%, and 82.8%, respectively. These results suggest that RT may provide a PFS benefit and extend the lifespan of ICIs in patients who experience oligoprogression. Regardless of PFS, however, overall survival in this population appears to be excellent.
- 5 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2481
Open AccessOligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
The breakthrough of a limited number of clones while on immune checkpoint inhibitors (ICIs), known as oligoprogression, has been previously described. The benefit of ablative radiation therapy (RT) directed at these clones, as opposed to changing systemic therapy, is unclear. We analyzed 30 patients with advanced solid tumors, the majority of whom (23/30, 86.7%) had either hepatocellular or urothelial carcinoma, who experienced oligoprogression on ICIs and were referred for RT. In this study, oligoprogression was defined as having experienced progression at three or fewer metastatic sites outside of the brain after achieving at least stable disease on ICIs for a minimum of three months. The median time to oligoprogression was 11.1 months from the initiation of immunotherapy. 24 patients had one oligoprogressive lesion and six had two. The median radiation dose delivered was 4650 cGy in a median of five fractions. The median progression-free survival (PFS) after RT was 7.1 months, and the time to oligoprogression was not a significant predictor of PFS2. 26 patients continued on ICIs after RT. While 17 patients subsequently progressed, 15 did so at three or fewer metastatic sites and could have theoretically stood to benefit from an additional course of salvage RT to further extend the lifespan of their ICIs. Overall survival at 6, 12, and 24 months was 100.0%, 96.3%, and 82.8%, respectively. These results suggest that RT may provide a PFS benefit and extend the lifespan of ICIs in patients who experience oligoprogression. Regardless of PFS, however, overall survival in this population appears to be excellent.
- 25 May 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (2) , 221-230
Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial
- 25 May 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 114 (2) , 221-230
Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial
- Open Access
- 4 January 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (2) , 100892
In Regard to Mattes et al.
- 4 January 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (2) , 100892
Open AccessIn Regard to Mattes et al.